New hope for hard-to-treat leukemias? early trial combines four drugs
Disease control
Recruiting now
This early-phase study tests a new drug (ABL001) combined with three other medicines (dasatinib, prednisone, and blinatumomab) for people with B-cell acute lymphoblastic leukemia or chronic myeloid leukemia that has a specific genetic marker (BCR-ABL positive). The main goal is t…
Phase: PHASE1 • Sponsor: Marlise Luskin, MD • Aim: Disease control
Last updated May 11, 2026 20:38 UTC